Literature DB >> 16025525

Fatigue of muscles weakened by death of motoneurons.

Christine K Thomas1, Inge Zijdewind.   

Abstract

Weakness is a characteristic of muscles influenced by the postpolio syndrome (PPS), amyotrophic lateral sclerosis (ALS), and spinal cord injury (SCI). The strength deficits relate to changes in muscle use and to the chronic denervation that can follow the spinal motoneuron death common to these disorders. PPS, ALS, and SCI also involve variable amounts of supraspinal neuron death, the effects of which on muscle weakness remains unclear. Nevertheless, weakness of muscle itself defines the functional consequences of these disorders. A weaker muscle requires an individual to work that muscle at higher than usual intensities relative to its maximal capacity, inducing progressive fatigue and an increased sense of effort. Little evidence is available to suggest that the fatigue commonly experienced by individuals with these disorders relates to an increase in the intrinsic fatigability of the muscle fibers. The only exception is when SCI induces chronic muscle paralysis. To reduce long-term functional deficits in these disorders, studies must identify the signaling pathways that influence neuron survival and determine the factors that encourage and limit sprouting of motor axons. This may ensure that a greater proportion of the fibers in each muscle remain innervated and available for use.

Entities:  

Mesh:

Year:  2006        PMID: 16025525     DOI: 10.1002/mus.20400

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  22 in total

1.  Contrasting effects of fatigue on multifinger coordination in young and older adults.

Authors:  Tarkeshwar Singh; Vladimir M Zatsiorsky; Mark L Latash
Journal:  J Appl Physiol (1985)       Date:  2013-06-06

2.  Electrical stimulation of transplanted motoneurons improves motor unit formation.

Authors:  Yang Liu; Robert M Grumbles; Christine K Thomas
Journal:  J Neurophysiol       Date:  2014-05-21       Impact factor: 2.714

3.  A Human-Based Functional NMJ System for Personalized ALS Modeling and Drug Testing.

Authors:  Xiufang Guo; Virginia Smith; Max Jackson; My Tran; Michael Thomas; Aakash Patel; Eric Lorusso; Siddharth Nimbalkar; Yunqing Cai; Christopher W McAleer; Ying Wang; Christopher J Long; James J Hickman
Journal:  Adv Ther (Weinh)       Date:  2020-08-11

4.  Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis.

Authors:  Steve Vucic; Arun V Krishnan; Matthew C Kiernan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-19       Impact factor: 10.154

5.  Effects of baclofen on motor units paralysed by chronic cervical spinal cord injury.

Authors:  Christine K Thomas; Charlotte K Häger-Ross; Cliff S Klein
Journal:  Brain       Date:  2009-11-10       Impact factor: 13.501

6.  Excitability and the safety margin in human axons during hyperthermia.

Authors:  James Howells; Dirk Czesnik; Louise Trevillion; David Burke
Journal:  J Physiol       Date:  2013-04-22       Impact factor: 5.182

7.  Motoneuron Death after Human Spinal Cord Injury.

Authors:  Robert M Grumbles; Christine K Thomas
Journal:  J Neurotrauma       Date:  2016-08-25       Impact factor: 5.269

8.  Motoneuron replacement for reinnervation of skeletal muscle in adult rats.

Authors:  Robert M Grumbles; Vania W Almeida; Gizelda T B Casella; Patrick M Wood; Kamondanai Hemstapat; Christine K Thomas
Journal:  J Neuropathol Exp Neurol       Date:  2012-10       Impact factor: 3.685

9.  Electrical stimulation of embryonic neurons for 1 hour improves axon regeneration and the number of reinnervated muscles that function.

Authors:  Yang Liu; Robert M Grumbles; Christine K Thomas
Journal:  J Neuropathol Exp Neurol       Date:  2013-07       Impact factor: 3.685

10.  Neurotrophic factors improve motoneuron survival and function of muscle reinnervated by embryonic neurons.

Authors:  Robert M Grumbles; Sanjay Sesodia; Patrick M Wood; Christine K Thomas
Journal:  J Neuropathol Exp Neurol       Date:  2009-07       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.